Becker O, Durand A, Chevrier M, Collet L, Gladieff L, Joly F, Sauterey B, Pomel C, Pautier P, Guillemet C, Sabatier R, Classe J-M, Petit T, Leblanc E, Marchal F, Colombo P-E, Barranger E, Savoye A-M, Bosquet L, Ray-Coquard I, Carton M, Colomban O, Rodrigues M Tumor-intrinsic chemosensitivity assessed by KELIM and prognosis by BRCA status in patients with advanced ovarian carcinomas. Int J Gynecol Cancer. 2025-01-06. doi:10.1136/ijgc-2024-005815
Simon L, Constanzo J, Terraza-Aguirre C, Ibn Elfekih Z, Berthelot J, Benkhaled B, Haute T, Pednekar K, Clark K, Emerson S, Atis S, Benedetti C, Langlois S, Marquant A, Prakash J, Wang A, Devoisselle J, Montier T, Djouad F, Pouget J, Lapinte V, Morille M Surface modification of extracellular vesicles with polyoxazolines to enhance their plasma stability and tumor accumulation. Biomaterials. 2025;313. doi:10.1016/j.biomaterials.2024.122748
Tabet I, Candiello E, Fenou L, Velazquez C, Jacot W, Ribeyre C, Sardet C, Theillet C Replication poison treated BRCA1-deficient breast cancers are prone to MRE11 over-resection resulting in single strand DNA accumulation and mitotic catastrophe.. Cancer Research. 2025;in press.
Laurent P-A, André F, Bobard A, Demaria S, Depil S, Eichmüller S, Fernandez-Palomo C, Foijer F, Galluzzi L, Guckenberger M, Harrington K, Herrera F, Huber P, Italiano A, Karam S, Kroemer G, Lambin P, Leuschner C, Mantovani A, Meylan E, Mondini M, Pittet M, Pouget J-P, Remon J, Sørensen C, Sotiriou C, Vanpouille-Box C, Weichselbaum R, Welsh J, Zitvogel L, Formenti S, Deutsch E Pushing the boundaries of radiotherapy-immunotherapy combinations: highlights from the 7th immunorad conference. Oncoimmunology. 2025;14(1):2432726. doi:10.1080/2162402X.2024.2432726
MHC-I-driven anti-tumor immunity counterbalances low absorbed doses of targeted radionuclide therapy. J Nucl Med. 2025 (in press).
Di Michele M, Attina A, Roux P-F, Laguesse S, Florido J, Houdeville M, Choquet A, Encislai B, Arena G, De Blasio C, Wendling O, Frenois F-X, Papon L, Stuani L, Fuentes M, Jahannault Talignani C, Rousseau M, Guégan J, Buscail Y, Dupré P, Michaud H-A, Rodier G, Bellvert F, Kulyk H, Ferraro Peyret C, Mathieu H, Close P, Rapino F, Chaveroux C, Pirot N, Rubio L, Torro A, Sorg T, Ango F, Hirtz C, Compan V, Lebigot E, Legati A, Ghezzi D, Nguyen L, David A, Sardet C, Lacroix M, Le Cam L E4F1 coordinates pyruvate metabolism and the activity of the elongator complex to ensure translation fidelity during brain development. Nat Commun. 2025;16(1):67. doi:10.1038/s41467-024-55444-y
Abba Moussa D, Vazquez M, Chable-Bessia C, Roux-Portalez V, Tamagnini E, Pedotti M, Simonelli L, Ngo G, Souchard M, Chentouf M, Gros N, Marsile-Medun S, Dinter H, Pugnière M, Martineau P, Varani L, Juan M, Calderon H, Naranjo-Gomez M, Pelegrin M Discovery of a pan anti-SARS-CoV-2 monoclonal antibody with highly efficient infected cell killing capacity for novel immunotherapeutic approaches. Emerg Microbes Infect. 2025;14(1):2432345. doi:10.1080/22221751.2024.2432345
Granier D, Perrier C, Leenhardt F, Faillie J-L, Senesse P [Preventing the risks of interaction between cancer treatments and complementary care strategies]. Bull Cancer. 2024-11-15. doi:10.1016/j.bulcan.2024.10.008
Falconi J, Strobel K, Djiane A, Lassus P [Drosophila as a model to study cancer biology]. Bull Cancer. 2024;111(9):880-892. doi:10.1016/j.bulcan.2024.05.005
Quénet F, Carrère S, Sgarbura O [Contribution of intraperitoneal chemotherapy in the treatment of colorectal peritoneal carcinoma. HIPEC, PIPAC, state of the art and future directions]. Bull Cancer. 2024;111(3):285-290. doi:10.1016/j.bulcan.2023.10.006
Rubira L, Donzé C, Fouillet J, Algudo B, Kotzki P, Deshayes E, Fersing C [68Ga]Ga-FAPI-46 synthesis on a GAIA® module system: Thorough study of the automated radiolabeling reaction conditions. Appl Radiat Isot. 2024;206. doi:10.1016/j.apradiso.2024.111211
de Pellegars-Malhortie A, Picque Lasorsa L, Mazard T, Granier F, Prévostel C Why Is Wnt/?-Catenin Not Yet Targeted in Routine Cancer Care?. Pharmaceuticals (Basel). 2024;17(7):949. doi:10.3390/ph17070949
Linares Díaz J, Edwards J, Deleu A-L, Giaj-Levra N, Prisciandaro E, Paesmans M, Berghmans T, Brandão M What Does N2 Lymph Node Involvement Mean for Patients with Non-Small Cell Lung Cancer (NSCLC)?-A Review of Implications for Diagnosis and Treatment. Cancers (Basel). 2024;16(15):2673. doi:10.3390/cancers16152673
El Osmani N, Prévostel C, Picque Lasorsa L, El Harakeh M, Radwan Z, Mawlawi H, El Sabban M, Shirinian M, Dassouki Z Vitamin C enhances co-localization of novel TET1 nuclear bodies with both Cajal and PML bodies in colorectal cancer cells. Epigenetics. 2024;19(1):2337142. doi:10.1080/15592294.2024.2337142
Bardia A, Hu X, Dent R, Yonemori K, Barrios C, O'Shaughnessy J, Wildiers H, Pierga J-Y, Zhang Q, Saura C, Biganzoli L, Sohn J, Im S-A, Jacot W, Begbie N, Ke J, Patel G, Curigliano G Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer. N Engl J Med. 2024;391(22):2110-2122. doi:10.1056/NEJMoa2407086
Souche C, Fouillet J, Rubira L, Donzé C, Sallé A, Dromard Y, Deshayes E, Fersing C Towards Optimal Automated 68Ga-Radiolabeling Conditions of the DOTA-Bisphosphonate BPAMD Without Pre-Purification of the Generator Eluate. J Labelled Comp Radiopharm. 2024-11-20. doi:10.1002/jlcr.4128
Bardiès M, Flux G, Sjögreen Gleisner K The Translation of Dosimetry into Clinical Practice: What It Takes to Make Dosimetry a Mandatory Part of Clinical Practice. J Nucl Med. 2024;65(12):1846-1847. doi:10.2967/jnumed.124.267742
Slaninová V, Heron-Milhavet L, Robin M, Jeanson L, Aissanou A, Kantar D, Tosi D, Bréhélin L, Gongora C, Djiane A The Hippo pathway terminal effector TAZ/WWTR1 mediates oxaliplatin sensitivity in p53 proficient colon cancer cells. BMC Cancer. 2024;24(1):587. doi:10.1186/s12885-024-12316-4
Bardiès M, Flux G, Platoni P, Koutsouveli E Symposium on molecular radiotherapy dosimetry: The first of a series?. Phys Med. 2024;120. doi:10.1016/j.ejmp.2024.103328
Pastre M, Occéan B-V, Boudousq V, Conejero I, Fabbro-Peray P, Collombier L, Mallet L, Lopez-Castroman J Serotonergic underpinnings of obsessive-compulsive disorder: A systematic review and meta-analysis of neuroimaging findings. Psychiatry Clin Neurosci. 2024-11-07. doi:10.1111/pcn.13760
Colombo P-E, Druet C, Mourregot A, Riou O, Rouanet P, Taoum C Robotic posterior pelvic exenteration for locally advanced rectal cancer-A video vignette. Colorectal Dis. 2024;26(10):1845-1848. doi:10.1111/codi.17147
Adenis A, Ghiringhelli F, Gauthier L, Mazard T, Evesque L, Evrard A, Chalbos P, Moussion A, Gourgou S, Ychou M Regorafenib plus FOLFIRINOX as first-line treatment for patients with RAS-mutant metastatic colorectal cancer (FOLFIRINOX-R trial): a dose-escalation study. Cancer Chemother Pharmacol. 2024;94(3):443-452. doi:10.1007/s00280-024-04682-4
Kayal G, Barbosa N, Marín C, Ferrer L, Fragoso-Negrín J-A, Grosev D, Gupta S, Hidayati N, Moalosi T, Poli G, Thakral P, Tsapaki V, Vauclin S, Vergara-Gil A, Knoll P, Hobbs R, Bardiès M Quality Assurance Considerations in Radiopharmaceutical Therapy Dosimetry Using PLANETDose: An International Atomic Energy Agency Study. J Nucl Med. 2024;65(1):125-131. doi:10.2967/jnumed.122.265340
Mazard T, Mollevi C, Loyer E, Léger J, Chautard R, Bouché O, Borg C, Armand-Dujardin P, Bleuzen A, Assenat E, Lecomte T Prognostic value of the tumor-to-liver density ratio in patients with metastatic colorectal cancer treated with bevacizumab-based chemotherapy. A post-hoc study of the STIC-AVASTIN trial. Cancer Imaging. 2024;24(1):77. doi:10.1186/s40644-024-00722-7
Boissière-Michot F, Chateau M-C, Lafont V, Crapez E, Sharma P, Roger P, Guiu S, Jacot W Prognostic value of tertiary lymphoid structures in triple-negative breast cancer: integrated analysis with the tumor microenvironment and clinicopathological features. Front Immunol. 2024;15. doi:10.3389/fimmu.2024.1507371
Institut de Recherche en Cancérologie de
